<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">Conventional enzyme replacement therapy with idursulfase for MPS II is ineffective against CNS disorders, because the enzyme cannot penetrate the brain through the BBB. Managing these disorders has, therefore, been a frustration in clinical practice and has left neuropathic MPS in something of a therapeutic impasse.
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref> Efforts have been made to improve enzyme delivery to the brain by way of intrathecal
 <xref rid="bib16" ref-type="bibr">
  <sup>16</sup>
 </xref> or intracerebroventricular
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> administration, but these efforts have reportedly had very limited success in achieving sufficient brain penetration.
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref>
</p>
